BOARD OF DIRECTORS

Our Board comprises nine Directors, including one executive Director, five non-executive Directors and three independent non-executive Directors.

The following table sets out information in respect of our Directors:

Name	Age	Position	Date of joining our Group	Date of appointment as Director	Roles and responsibilities
Executive Director					
Dr. Qunsheng JI (冀群升)	62	Executive Director and chief executive office	August 7, 2022	October 12, 2022	Providing overall guidance on business direction and management of the Group
Non-executive Directors					
Dr. David Guowei WANG (王國瑋)	64	Chairman of the Board and non-executive Director	June 30, 2021	June 30, 2021	Participating in formulating the Company's corporate and business strategies
Dr. Wei LI (李偉)	54	Non-executive Director	May 14, 2021	May 14, 2021	Participating in formulating the Company's corporate and business strategies
Mr. Diyong XU (徐荻勇)	43	Non-executive Director	June 30, 2021	June 30, 2021	Participating in formulating the Company's corporate and business strategies
Mr. Quanhong YUAN (苑全紅)	51	Non-executive Director	June 12, 2023	June 12, 2023	Participating in formulating the Company's corporate and business strategies
Dr. Douglas McIntosh FAMBROUGH III	56	Non-executive Director	July 13, 2022	July 13, 2022	Participating in formulating the Company's corporate and business strategies
Independent Non-executive Directors					
Ms. Christine Shaohua LU-WONG (盧韶華)	56	Independent non-executive Director	[REDACTED]	[REDACTED]	Supervising and providing independent judgment to the Board
Dr. Chris Xiangyang LU (呂向陽)	61	Independent non-executive Director	[REDACTED]	[REDACTED]	Supervising and providing independent judgment to the Board
Dr. Paul Herbert CHEW M.D.	73	Independent non-executive Director	[REDACTED]	[REDACTED]	Supervising and providing independent judgment to the Board

Executive Director

Dr. Qunsheng JI (冀群升), aged 62, is our executive Director and Chief Executive Officer. He is primarily responsible for providing overall guidance on business direction and management of the Group. He was appointed as a Director in October 2022 and re-designated as an executive Director in September 2025. Dr. JI has also been serving as the chief executive officer of Sirius U.S. and Sirius Australia, the chief executive officer of Sirius Shanghai, as well as the chief executive officer and a director of Sirius Hong Kong since August 2022, respectively. He was appointed as the manager of Sirius Shanghai in September 2025.

Dr. JI has over 25 years of experience in drug discovery, translational medicine and business leadership. He worked at the school of medicine at Vanderbilt University as a research instructor from 1996 to 1997. Dr. JI worked at OSI Pharmaceuticals from 2001 to 2007 with his last position as a senior research investigator at the oncology department. He worked at AstraZeneca from October 2007 to October 2014 with his last position as a director, head of bioscience. He was the vice president and the head of oncology and immunology unit at WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (a company listed on the Stock Exchange, stock code: 2359) from October 2014 to August 2022.

Dr. JI obtained his bachelor's degree in clinical medicine and master's degree in cell biology from Southern Medical University in China in July 1986 and July 1989, respectively. He obtained his Doctor of Medicine degree in cellular biology from Peking Union Medical College in China in January 1996.

Non-Executive Directors

Dr. David Guowei WANG (王國瑋), aged 64, is our Chairman of the Board and non-executive Director. He is primarily responsible for participating in formulating the Company's corporate and business strategies. He was appointed as a Director in June 2021 and re-designated as a non-executive Director in September 2025. Dr. WANG has also been serving as a director of Sirius Hong Kong since December 2021.

Dr. WANG has extensive experience in the medical industry. Dr. WANG is a partner and senior managing director of Asia at OrbiMed Advisors LLC, an investment fund with a focus on healthcare industry, where he has worked since August 2011. From April 2006 to July 2011, he served as managing director at WI Harper Group. Dr. WANG has served as a director of Sichuan Biokin Pharmaceutical Co., Ltd (四川百利天恒藥業股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 688506) since September 2017. He has also been a non-executive director of Edding Genor Group Holdings Limited (億騰嘉和醫藥集團有限公司) (a company listed on the Stock Exchange, stock code: 6998) since December 2025. Further, he was appointed as a non-executive director of AK Medical Holdings Limited (愛康醫療控股有限公司) (a company listed on the Stock Exchange, stock code: 1789) since February 2016. He was appointed as director of Gaush Meditech Ltd (高視醫療科技有限公司) (a company listed on the Stock Exchange, stock code: 2407) in December 2017 and re-designated as a non-executive director in November 2021.

Dr. WANG was a director of Gracell Biotechnologies Inc. (a company previously listed on the NASDAQ Global Market, ticker symbol before delisting: GRCL) from March 2020 to February 2024 and a director of Sinovac Biotech Ltd. (科興控股生物技術有限公司) (a company listed on the NASDAQ, ticker symbol: SVA) from February 2025 to July 2025.

Dr. WANG received his bachelor's degree in medicine from Beijing Medical University (北京醫科大學) (currently known as Peking University Health Science Center (北京大學醫學部)) in China in July 1986. He received his Doctor of Philosophy degree in developmental biology from California Institute of Technology in the United States in June 1995.

Dr. Wei LI (李偉), aged 54, is our non-executive Director. He was initially involved in the Company formation and is primarily responsible for the formation of Company's corporate and business strategies. He was appointed as a Director in May 2021 and re-designated as a non-executive Director in September 2025.

Dr. Li has extensive experience in investing in the biotech industry. He is a founding partner of Creacion Ventures L.P. since April 2020. He is also a founding partner and the managing partner at WuXi Healthcare Ventures since July 2015. He was also formerly the managing partner of 6 Dimensions Capital and an investment professional at Fidelity Biosciences.

Dr. Li has been a director of CStone Pharmaceuticals Therapeutics (a company listed on the Stock Exchange, stock code: 2616) since December 2015 and was re-designated as a non-executive director in October 2018 and he was appointed as the chairman in May 2022 subsequently. He was appointed as a non-executive director of Ocumension Therapeutics (a company listed on the Stock Exchange, stock code: 1477) in April 2018 and was re-designated an executive director from April 2020 to July 2021, then continued to serve as its non-executive director until January 2025. He is also currently a director of QuantX Biosciences.

Dr. Li received a Ph.D. in chemistry from Harvard University in the United States in November 1998 and a master's degree in business administration from the J. L. Kellogg School of Management at Northwestern University in the United States in June 2003. He graduated with a Bachelor of Science in chemical physics from the University of Science and Technology of China (中國科學技術大學) in China in June 1993.

Mr. Diyong XU (徐荻勇), aged 43, is our non-executive Director. He is primarily responsible for participating in formulating the Company's corporate and business strategies. He was appointed as a Director in June 2021 and re-designated as a non-executive Director in September 2025. He is also a director of Sirius Hong Kong since December 2021.

Mr. Xu is currently a partner at OrbiMed Advisors LLC, an investment firm which he joined in August 2012. Mr. Xu worked for Lazard Freres & Co. in its Healthcare Investment Banking Group from June 2010 to July 2012.

Mr. Xu has been a director of Q32 Bio, Inc. (a company listed on the NASDAQ, ticker symbol: QTTB) since August 2020. He has also been serving as a director of OnCusp Therapeutics, Inc. and Pinnacle Medicines since December 2023 and April 2024, respectively. In September 2025, Mr. Xu became a director of Frontera Therapeutics.

Mr. Xu obtained a master's degree in management science and engineering from Stanford University in the United States and a master's degree in molecular and cellular biology from Dartmouth College in the United States in June 2010 and November 2008, respectively. He received a bachelor's degree in biology from Zhejiang University (浙江大學) in China in June 2004.

Mr. Quanhong YUAN (苑全紅), aged 51, is our non-executive Director. He is primarily responsible for participating in formulating the Company's corporate and business strategies. He was appointed as a Director in June 2023 and re-designated as a non-executive Director in September 2025.

Mr. Yuan is the founding member and the chief executive officer of Shanghai Hankang Private Equity Management Co., Ltd. (上海漢康私募基金管理有限公司) since October 2010. He has also been serving as a manager of Hankang Biotech III, LLC (the general partner of Hankang Biotech) and Pole Star Biotech LLC (the general partner of Splendid Biotech) since January 2021 and September 2021, respectively. Mr. Yuan has more than 15 years of investment experience in the pharmaceutical industry in the Greater China and has managed investments and M&A in biotech, medical service and vaccines.

Mr. Yuan obtained a master's degree in business administration from China Europe International Business School (中歐國際工商學院) in China in March 2008 and a master's degree in management science and engineering from Zhejiang University (浙江大學) in China in March 2001. He graduated with a bachelor's degree in materials science and engineering from Zhejiang University (浙江大學) in China in July 1996.

Dr. Douglas McIntosh FAMBROUGH III, aged 56, is our non-executive Director. He is primarily responsible for participating in formulating the Company's corporate and business strategies. He was appointed as an independent Director in July 2022 and re-designated as a non-executive Director in September 2025. He is also a director of Sirius Hong Kong since December 2021.

Dr. Fambrough has a wealth of experience in the biotechnology sector in the United States. He co-founded and was the president and chief executive officer of Dicerna Pharmaceuticals, Inc. ("**Dicerna**"), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, from May 2010 to January 2022. Under Dr. Fambrough's leadership, Dicerna achieved remarkable success as a pioneer in the field of RNA interference (RNAi) therapeutics. During his time as president and CEO from May 2010 to December 2021, Dr. Fambrough developed and transformed Dicerna into a second-generation RNAi leader, leveraging its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules to develop innovative treatments for rare diseases and genetically defined cancers. Dr. Fambrough spearheaded Dicerna's strategic vision, leading to multiple world-class partnerships, including a 2019 collaboration with Novo Nordisk, to develop RNAi-based solutions for chronic liver diseases, type 2 diabetes, and obesity. Under his leadership, Dicerna expanded its clinical pipeline technology multiple FDA-approved product RIVFLOZA™. In 2018, Dicerna formed a collaboration with Eli Lilly (NYSE: LLY) to discover, develop, and commercialize RNA interference (RNAi) therapies for cardio-metabolic disease, neurodegeneration, and pain, leveraging Dicerna's GalXC RNAi platform. In 2019, Dicerna formed a collaboration with Roche (SWX: ROG) to develop RNA interference (RNAi) therapies for chronic hepatitis B, with Roche paying $200 million upfront and gaining rights to Dicerna's DCR-HBVS drug candidate and an option for future HBV targets. In November 2021, Dicerna was acquired by Novo Nordisk for US$3.3 billion in an all-cash deal, representing a significant premium to Dicerna's closing stock price. Dr. Fambrough's scientific expertise, strategic leadership, and business acumen were instrumental in positioning Dicerna as a leader in the RNAi space, leading to one of the most prominent biotech acquisitions of 2021.

Dr. Fambrough also has extensive experience as a senior executive and has served on the boards of across multiple innovative biotechnology companies, where he has consistently demonstrated expertise in driving scientific breakthroughs, forging strategic partnerships, and delivering exceptional business outcomes. His leadership in the RNAi therapeutics space, combined with a proven track record in genomics and life sciences investments, reinforced his status as a visionary in the biotech industry. More specifically, from 2000 to May 2010, he held various positions at Oxford Bioscience Partners, a life science venture capital firm, most recently as a general partner, where he has specialized in financing innovative life science technology companies. While at Oxford Bioscience Partners, Dr. Fambrough led the investment in the first generation RNA interference company Sirna Therapeutics, an early RNAi company that was acquired by Merck & Co., Inc (NYSE: MRK) for $1.1 billion. He played a pivotal role not only in managing the investment but also in restructuring Ribozyme Pharmaceuticals, Sirna Therapeutics' predecessor company, as well as executing the acquisition by Merck & Co., Inc. Among his other investments are high-throughput DNA sequencing pioneer Solexa, Inc. (NASDAQ: SLXA); which was acquired by Illumina (NASDAQ: ILMN); Xencor (NASDAQ: XNCR), which engineers antibody Fc domains to enhance drug properties. Prior to joining at Oxford Bioscience Partners, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genomic Research, now known as the Broad Institute.

Dr. Fambrough was previously a director of Oncorus, Inc. (NASDAQ: ONCR), which has dissolved and delisted. Due to poor prospects for its business operations, Oncorus, Inc. was voluntarily dissolved and delisted on January 2, 2024 after its shareholders approved the liquidation and dissolution. Dr. Fambrough confirmed that (i) to the best of his knowledge, information and belief, Oncorus, Inc. was solvent and had no material non-compliances immediately prior to the dissolution; (ii) there is no wrongful act on his part leading to the dissolution; (iii) he is not aware of any outstanding or potential claim that has been or will be made against him as a result of the dissolution; and (iv) no misconduct or misfeasance had been involved in the dissolution.

Dr. Fambrough received a Ph.D. degree in genetics from the University of California, Berkeley in the United States in December, 1996 and a bachelor's degree in biology from Cornell University in the United States in May, 1991.

Independent Non-executive Directors

Ms. Christine Shaohua LU-WONG (盧韶華), aged 56, was appointed as an independent non-executive Director effective as of [**REDACTED**] and is primarily responsible for supervising and providing independent judgment to the Board.

Ms. LU-WONG has more than 15 years of financial management experience at various listed companies. She has been an independent non-executive director of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (a company listed on the Stock Exchange, stock code: 2359) since May 2023 and the chairperson of its audit committee since June 2023. She has also been an independent non-executive director of GenFleet Therapeutics (Shanghai) Inc. (a company listed on the Stock Exchange, stock code: 2595), the chairperson of its audit committee and a member of its nomination committee since September 2025.

She was the chief financial officer of WuXi Biologics (Cayman) Inc. (a company listed on the Stock Exchange, stock code: 2269) from January 2016 to August 2021. From November 2012 to December 2015, she served as the chief financial officer of Xueda Education Group (學大教育集團) (a company previously listed on the NYSE, ticker symbol: XUE), which was primarily engaged in the provision of personalized tutoring services for primary and secondary school students in China, and was responsible for overall financial management of the company. From 2010 to 2012, she served as the chief financial officer of HiSoft Technology International Limited (海輝軟件(國際)集團) (currently known as Pactera Technology International Ltd.) (a company previously listed on the NASDAQ, ticker symbol: HSFT), which was primarily engaged in the provision of consulting and technology services, and was responsible for overall financial management of the company. From 2007 to 2009, she served as the vice president of finance of WuXi PharmaTech (Cayman) Inc. (a company previously listed on the NYSE, ticker symbol: WX).

Ms. LU-WONG obtained a master's degree in business administration (accounting) from Golden Gate University in San Francisco in April 1994 and a bachelor's degree in foreign trade and economics from Guangdong University of Foreign Studies (廣東外語外貿大學) in China in July 1990.

Ms. LU-WONG obtained the qualification as a certified public accountant from the State Board of Accountancy of the Department of Consumer Affairs of the State of California, the United States, in 1998.

Dr. Chris Xiangyang LU (呂向陽), aged 61, was appointed as an independent non-executive Director effective as of [**REDACTED**] and is primarily responsible for supervising and providing independent judgment to the Board.

Dr. Lu has over 20 years of drug discovery and development experience in the biotechnology and pharmaceutical industry. He is the founder of Laekna, Inc. (來凱醫藥有限公司) (a company listed on the Stock Exchange, stock code: 2105) and has been as its executive director since July 2016. He is also the chairman and chief executive officer of Laekna, Inc. Further, Dr. Lu is a director of Laekna Limited, Laekna Pharmaceutical Ningbo Co., Ltd. (來凱製藥(寧波)有限公司) and Laekna Therapeutics Shanghai Co., Ltd. (來凱醫藥科技(上海)有限公司), subsidiaries of Laekna, Inc., since July 2016.

Dr. Lu had worked in Ontogeny, Inc., a biotechnology company, in 1998. From September 2003 to March 2016, he worked at Novartis Institutes for BioMedical Research ("**NIBR**") and China Novartis Institutes for BioMedical Research Co., Ltd. (諾華(中國)生物醫學研究有限公司) ("**CNIBR**"). He was bestowed Novartis VIVA Award with "Novartis Leading Scientist" honorary title in November 2012. His last position there was executive director and was responsible for leading the drug discovery platform and multiple disease research programs. NIBR and CNIBR are under Novartis AG. He was formerly a venture partner at Frontline Bioventures (通和資本), a venture capital firm focusing on investment in healthcare industry, responsible for providing general professional advice from biotechnology perspective to the investment portfolio of Frontline Bioventures on a part-time basis.

Dr. Lu received his bachelor of science degree and master of science degree in biology department from Nankai University (南開大學) in China in July 1985 and June 1988, respectively. Dr. Lu obtained the Doctor of Philosophy degree from the school of medicine of the University of North Carolina at Chapel Hill in the United States in August 1995. Dr. Lu was a postdoctoral fellow at Harvard University in the United States from 1995 to 1998.

Dr. Paul Herbert CHEW M.D., aged 73, was appointed as an independent non-executive Director effective as of [**REDACTED**] and is primarily responsible for supervising and providing independent judgment to the Board.

Dr. Chew was an independent non-executive director of CStone Pharmaceuticals (a company listed on the Stock Exchange, stock code: 2616) from February 2019 to June 2025. Dr. Chew has also been the adviser chief medical officer and has been on the board of directors for Phesi since April 2018, an innovative firm that optimizes clinical trial design with novel technology. Dr. Chew has been the adviser chief medical officer for CorMedix, Inc, utilizing a taurolidine-based platform to prevent infection in high risk patients. Dr. Chew has served on the advisory boards at the Center for Public Health, George Washington School of Public Health as well as ArisGlobal, a leading life sciences software provider that speeds drug development. He has served as a member of the board of trustees for the U.S. Pharmacopeia that sets quality standards for U.S. drugs, foods and dietary supplements, enforced by the U.S. FDA but whose standards are also followed by more than 140 countries.

He joined Omada Health, Inc. as Chief Medical Officer in January 2017, and was appointed a member of the board of trustees of BioNJ Inc. in March 2015. Dr. Chew was a Senior Vice President, Global Chief Medical Officer and Head of Medical Affairs at Sanofi (a company listed on the New York Stock Exchange, ticker symbol: SNY and Euronext Paris, ticker symbol: SAN), a global pharmaceutical company based in Paris, from 2013 to 2016. In his position as Global Chief Medical Officer, he represented Sanofi as a member company in the PhRMA Science & Regulatory Affairs Executive Committee. He served as Senior Vice President, Chief Medical Officer/Chief Scientific Officer at Sanofi from 2004 to 2012. Between 2001 and 2003, he held the position of Vice President, Vice President Global Cardiovascular — Thrombosis Development — Aventis, responsible for Lovenox, Lantus, and the therapeutic development portfolio. In several roles at Sanofi, Dr. Chew worked closely with payers, patient groups, and the full range of healthcare stakeholders.

Dr. Chew served as a member of the Institute of Medicine Value & Science-Driven Healthcare Roundtable, and was certified by the American Board of Internal Medicine in Internal Medicine and Cardiovascular Disease.

Dr. Chew graduated with a Doctor of Medicine and a Bachelor of Arts from the Johns Hopkins University School of Medicine in the United States in May 1977 and May 1973, respectively

SENIOR MANAGEMENT

The following table sets forth information about our senior management:

Name	Age	Position	Date of joining our Group	Date of appointment as senior management	Roles and responsibilities
Dr. Qunsheng JI (冀群升)	62	Executive Director and Chief Executive Office	August 7, 2022	August 7, 2022	Providing overall guidance on business direction and management of the Group

Name	Age	Position	Date of joining our Group	Date of appointment as senior management	Roles and responsibilities
Dr. Curt William BRADSHAW	60	Chief Scientific Officer	July 14, 2021	July 14, 2021	Overseeing the scientific affairs and staff management of our Group
Dr. Patrick YUE M.D. (于沛川)	51	Chief Medical Officer	July 8, 2024	July 8, 2024	Overseeing the clinical activities and staff management of our Group
Mr. Hailei LU (陸海磊)	39	Chief Financial Officer	August 19, 2025	August 19, 2025	Capital market, business development, overall finance, internal controls and corporate management of our Group

Dr. Qunsheng JI (冀群升), aged 62, is our executive Director and Chief Executive Officer. He is primarily responsible for providing overall guidance on business direction and management of the Group. He was appointed as a Director in October 2022 and re-designated as an executive Director in September 2025. See "— Board of Directors — Executive Director" for his biographical details.

Dr. BRADSHAW Curt William, aged 60, was appointed as the Chief Scientific Officer of our Company in July 2021 and is responsible for overseeing the scientific affairs and staff management of our Group.

Dr. BRADSHAW has over 20 years of experience in drug and chemical development. Dr. BRADSHAW joined CovX Pharmaceuticals Inc as a vice president of research and development in September 2002. He later joined Traversa Therapeutics, Inc. as the chief scientific officer in December 2009. Later, Dr. BRADSHAW served as the president and the chief scientific officer at Solstice Biologics. In 2018, he founded Tallac Therapeutics, Inc. and had served as the chief scientific officer and a member of the board of directors until October 2019. From November 2019 to November 2020, he was the chief scientific officer of Arrowhead Pharmaceuticals, Inc. (a company listed on NASDAQ, ticker symbol: ARWR). Dr. BRADSHAW served as the chief scientific officer of NeuBase Therapeutics, Inc. (a company listed on NASDAQ, ticker symbol: NBSE) from December 2020 to June 2021.

Dr. BRADSHAW obtained a Ph.D. degree in organic chemistry from Texas A&M University in the United States in April 1992.

Dr. Patrick YUE M.D. (于沛川), aged 51, was appointed as the Chief Medical Officer of our Company in July 2024 and is primarily responsible for overseeing the clinical activities and staff management of our Company.

Dr. Yue has extensive leadership experience in clinical development. He previously worked at Gilead Sciences, Inc. (a company listed on NASDAQ, ticker symbol: GILD). He was an executive director of clinical development at Portola Pharmaceuticals, Inc. from July 2016 to October 2020. Dr. Yue served as an executive director of clinical science at Global Blood Therapeutics, Inc. (later acquired by Pfizer Inc.) from October 2020 to February 2023. Prior to joining the Group, he was a senior vice president at Centessa Pharmaceuticals plc (a company listed on NASDAQ, ticker symbol: CNTA) and a director of ApcinteX Limited (a subsidiary of Centessa Pharmaceuticals plc) from February 2023 to June 2024.

Dr. Yue obtained a Bachelor of Science in biology and chemistry form California Institute of Technology in the United States in June 1995 and a Doctor of Medicine from the school of medicine of Washington University in the United States in May 1999. Dr. Yue also completed his medical internship and residency at Beth Israel Deaconess Medical Center in the United States from June 1999 to June 2002 and received specialty training in cardiovascular medicine at Stanford University School of Medicine from July 2002 to June 2005.

Dr. Yue has been licensed as a physician and surgeon by the Medical Board of California of the United States since July 12, 2002, which is currently set to expire on April 30, 2026.

Mr. Hailei LU (陸海磊), aged 39, was appointed as the Chief Financial Officer of our Company in August 2025 and is primarily responsible for capital market, business development, overall finance, internal controls and corporate management of our Group.

Mr. LU brings more than 15 years of expertise in capital market, mergers and acquisitions, business development and financial management. Prior to joining the Company, Mr. LU held senior positions at several leading financial institutions and a pharmaceutical company, including Haisco Pharmaceutical Group Co., Ltd. (海思科醫藥集團股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 2653) from February 2024 to August 2025, the investment banking division at Goldman Sachs (Asia) L.L.C. from June 2015 to September 2023, the structured finance department at Crédit Agricole Corporate and Investment Bank from February 2011 to April 2014 and the audit department at Deloitte Touche Tohmatsu from January 2009 to January 2011.

Mr. LU obtained a bachelor's degree in business administration from the Hong Kong University of Science and Technology in Hong Kong in December 2008 and a master's degree in business administration from the University of Chicago Booth School of Business in the United States in June 2016.

Directors' and Senior Management's Interests

Save as disclosed above in this section, none of our Directors or senior management has been a director of any public company the securities of which are listed on any securities market in Hong Kong or overseas in the three years immediately preceding the date of this Document.

Save as disclosed above in this section, to the best of the knowledge, information and belief of our Directors having made all reasonable enquiries, there was no other matter with respect to the appointment of our Directors that needs to be brought to the attention of our Shareholders and there was no information relating to our Directors that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

As of the Latest Practicable Date, save for the interests in the Shares of our Company held directly by Dr. JI and Dr. Douglas McIntosh FAMBROUGH III and indirectly by Mr. Quanhong Yuan, which are disclosed in the paragraphs headed "Appendix IV — Statutory and General Information — C. Further Information about Our Directors and Substantial Shareholders" in this Document, none of our Directors held any interest or short position in the shares, underlying shares and debentures of our Company or any associated corporation (within the meaning of Part XV of the SFO).

Save as disclosed above in this section, as of the Latest Practicable Date, none of our Directors or senior management is related to other Directors or senior management of our Company.

COMPANY SECRETARY

Ms. Pui Ching CHAN (陳佩貞) was appointed the company secretary of our Company effective as of [**REDACTED**]. Ms. Chan has over 16 years of experience in company secretary and corporate governance field. She is a senior manager of Company Secretarial Services of Tricor Services Limited, a member of Vistra Group. She is responsible for providing professional corporate services to Hong Kong listed companies. Ms. Chan obtained her bachelor's degree in social sciences in December 2003 from The University of Hong Kong. She is a Chartered Secretary, a Corporate Governance Professional and an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

BOARD COMMITTEES

We have established three Board Committees in accordance with the Articles of Association and the Corporate Governance Code, namely the Audit and Corporate Governance Committee, the Nomination Committee and the Remuneration Committee, each with effect from the [**REDACTED**].

Audit and Corporate Governance Committee

We have established an Audit and Corporate Governance Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code. The Audit and Corporate Governance Committee consists of three Directors, namely Ms. Christine Shaohua LU-WONG, Dr. Chris Xiangyang LU and Dr. Douglas McIntosh FAMBROUGH III with Ms. Christine Shaohua LU-WONG serving as the chairperson. Ms. Christine Shaohua LU-WONG has the appropriate professional experiences as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit and Corporate Governance Committee include, but are not limited to: (i) proposing the appointment or change of external auditors to our Board, monitoring the independence of external auditors and evaluating their performance; (ii) examining the financial information of the Company and reviewing financial reports and statements of the Company; (iii) examining the financial reporting system, the risk management and internal control system of the Company, overseeing their rationality, efficiency and implementation and making recommendations to our Board; (iv) reviewing the Company's conflict-of-interest declarations from Directors and senior management, ensuring transparency and adherence to the established conflict-of-interest policies, and approving or recommending measures to address identified conflicts; (v) monitoring the implementation of processes to prevent and manage potential conflicts of interest, including monitoring any interests of Directors and senior management in competitors of the Company, to safeguard the Company's integrity and corporate governance standards; and (vi) dealing with other matters that are authorized by the Board.

Nomination Committee

We have established a Nomination Committee with written terms of reference in compliance with Rule 3.27A of the Listing Rules and the Corporate Governance Code. The Nomination Committee consists of three Directors, namely Dr. David Guowei WANG, Dr. Chris Xiangyang LU and Dr. Paul Herbert CHEW with Dr. David Guowei WANG serving as the chairperson. The primary duties of the Nomination Committee include, but are not limited to: (i) conducting extensive search and providing our Board with suitable candidates for our Directors and other members of the senior management; (ii) reviewing the structure, size and composition of our Board (including but not limited to, gender, age, cultural and educational background, ethnicity, skills, knowledge and experience) at least annually and make recommendations on any proposed changes to the Board to complement the Company's corporate strategy; (iii) researching and developing standards and procedures for the election of our Board members and members of the senior management, and making recommendations to our Board; (iv) assessing the independence of the independent non-executive Directors; and (v) dealing with other matters that are authorized by the Board.

Remuneration Committee

We have established a Remuneration Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code. The Remuneration Committee consists of three Directors, namely Dr. Wei LI, Dr. Paul Herbert CHEW and Ms. Christine Shaohua LU-WONG with Dr. Paul Herbert CHEW serving as the chairperson. The primary duties of the Remuneration Committee include, but are not limited to: (i) advising our Board on the overall remuneration plan and structure of our Directors and senior management and the establishment of transparent and formal procedures for determining the remuneration policy of the Company; (ii) monitoring the implementation of the remuneration system of the Company; (iii) making recommendations on the remuneration packages of our Directors and senior management; and (iv) dealing with other matters that are authorized by the Board.

KEY TERMS OF EMPLOYMENT CONTRACT

We normally enter into (i) an employment contract, (ii) a non-competition agreement, (iii) a confidentiality agreement and (iv) an intellectual property agreement with certain of our senior management members. The key terms of such contracts are set forth below.

Terms

We normally enter into a three-year to five-year employment contract with our senior management members.

Non-competition

The non-competition obligations shall subsist throughout the employee's period of employment and up to two years after termination of employment, depending on seniority. During the non-competition period, the employee shall not, directly or indirectly, accept employment or hold any position, including but not limited to shareholders, partners, directors, supervisors, employees, agents, consultants, etc., of any other natural person, legal entity or other economic organization that produces or operates the same, similar or competing products, or engages in the same, similar or competing business, with our Company.

Confidentiality

Trade Secrets: The employee shall keep trade secrets, namely business-related information or technology-related information (including but not limited to operational information, marketing proposal, purchases information, pricing policy, financial information, list of customers, business plan, information of research and development etc.) of our Company in confidence.

Obligation and duration: The employee shall not divulge or otherwise disclose any trade secrets to any third party or permit others to use our trade secrets, disclose our trade secrets to irrelevant staffs within our Company, use the trade secrets for his/her or third party's benefits, or duplicate documents or copies of documents that contain our trade secrets. Such obligation of confidentiality shall subsist for the term of his or her employment and regardless of the reason of departure, the employee shall return all materials containing trade secrets to our Company or destruct them under Company's supervision.

Intellectual Property Rights

All intellectual property related to an employee's duties, created during his/her period of employment and including, but not limited to, patent rights, rights to patent applications, trademark rights, rights to trademark applications, and copyrights, shall be exclusively owned by the Company. Employees shall retain the right of authorship

CORPORATE GOVERNANCE CODE

The Company is committed to achieving a high standard of corporate governance with a view to safeguarding the interests of our Shareholders. To accomplish this, the Company expects to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules upon the [**REDACTED**].

BOARD DIVERSITY POLICY

We have adopted the board diversity policy which sets out the objective and approach for achieving and maintaining the diversity of the Board in order to enhance its effectiveness. In accordance with the board diversity policy, the Company seeks to achieve board diversity by taking into account a number of factors, including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and/or length of service. The ultimate selection of Board candidates will be based on merit and potential contribution to our Board having due regard to the benefits of diversity on the Board and also the specific needs of the Company without focusing on a single diversity aspect. Our Directors have a balanced mix of knowledge and skills, including overall management and strategic development as well as knowledge and experience in areas such as medicine and pharmaceutical research. They obtained degrees in various areas including, among others, medicine, biology, business administration, economics, and accounting. Furthermore, our Board has a diverse age and gender representation. Our Board currently comprises one female Director and eight male Directors, ranging from 43 years old to 73 years old.

With regard to gender diversity on the Board, we recognize the particular importance of gender diversity. We have taken and will continue to take steps to promote and enhance gender diversity at all levels of the Company, including but without limitation at our Board and senior management levels. We will maintain a focus on gender diversity when recruiting staff at the mid to senior level so as to develop a pipeline of potential female successors to our Board. The Group will also identify and select several female individuals with a diverse range of skills, experience and knowledge in different fields from time to time, and maintain a list of such female individuals who possess qualities to become our Board members, which will be reviewed by our nomination committee periodically to maintain gender diversity of our Board. Taking into account our existing business model and specific needs as well as the different background of our Directors, the composition of our Board satisfies our board diversity policy.

Upon the [**REDACTED**], the Nomination Committee will from time to time discuss and agree on expected goals to ensure board diversity, and review and, where necessary, make recommendations to the Board on appropriate updates to the board diversity policy to ensure that the policy remains effective. The Company will disclose the biographical details of each Director and report on the implementation of the board diversity policy (including whether we have achieved board diversity) in its annual corporate governance report.

REMUNERATION OF DIRECTORS AND SENIOR MANAGEMENT

We normally enter into an employment contract with a term up to 3 years with our senior management members and other key personnel. For details on the service contracts and appointment letters signed between the Company and our Directors, please refer to the section "Statutory and General Information — C. Further Information about Our Directors and Substantial Shareholders" in Appendix IV to this Document. Our Directors and senior management receive compensation in the form of salaries, allowances, bonuses and other benefits in kind, including our contribution to the pension scheme.

For information on remuneration of Directors during the Track Record Period, as well as information on remuneration of the five highest paid individuals of our Group, see Notes 9 and 10 to the Accountants' Report.

During the Track Record Period, (i) no amount was paid to, or receivable by, our Directors or the five highest paid individuals as an inducement to join, or upon joining our Group, (ii) no compensation was paid to, or receivable by, our Directors or past Directors or the five highest paid individuals for the loss of office as director of any member of our Group or any other office in connection with the management of the affairs of any member of our Group, and (iii) none of our Directors waived or agreed to waive any emoluments. Our Directors' remuneration is determined with reference to the relevant Director's experience and qualifications, level of responsibility, performance and the time devoted to our business, and the prevailing market conditions.

It is estimated that remuneration and benefits in kind equivalent to approximately RMB23.0 million in aggregate will be paid and granted to our Directors by us in respect of the financial year ending December 31, 2026 under arrangements in force as at the date of this Document.

Except as disclosed in this document, no Director has been paid in cash or shares or otherwise by any person either to induce him to become, or to qualify him as a Director, or otherwise for service rendered by him in connection with the promotion or formation of us.

SHARE SCHEMES

We have adopted the Equity Incentive Plan and the [Post-[**REDACTED**] Equity Incentive Plan]. For further details, please see "Statutory and General Information — D. Equity Incentive Plan" and "Statutory and General Information — E. Post-[**REDACTED**] Equity Incentive Plan" in Appendix IV to this Document.

COMPLIANCE ADVISER

The Company has appointed Somerley Capital Limited as its compliance adviser pursuant to Rule 3A.19 of the Listing Rules. In compliance with Rule 3A.23 of the Listing Rules, the Company must consult with and, if necessary, seek advice from the compliance adviser on a timely basis in the following circumstances:

- before the publication of any regulatory announcement, circular or financial report;
- where a transaction, which might be a notifiable or connected transaction, is contemplated including share issues, sales or transfers of treasury shares and share repurchases;
- where we propose to apply the [**REDACTED**] of the [**REDACTED**] in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate or other information in this document; and
- where the Stock Exchange makes an inquiry of us in respect of unusual price movement or trading volume or other issues under Rule 13.10 of the Listing Rules.

The term of appointment of the compliance adviser will commence on the [**REDACTED**] and end on the date on which the Company distributes its annual report in respect of its financial results for the first full financial year commencing after the [**REDACTED**].

COMPETITION

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules. From time to time our non-executive Directors may serve on the boards of both private and public companies within the broader healthcare and biopharmaceutical industries. However, as these non-executive Directors are not members of our executive management team, we do not believe that their interests in such companies as directors would render us incapable of carrying on our business independently from the other companies in which these non-executive Directors may hold directorships from time to time.

CONFIRMATION FROM OUR DIRECTORS

Rule 3.09D of the Listing Rules

Each of our Directors obtained the legal advice referred to under Rule 3.09D of the Listing Rules in September 2025. Each of them confirms that he or she understands his or her obligations as a director of a [**REDACTED**] issuer.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he/she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointments.